Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167917163> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2167917163 endingPage "170" @default.
- W2167917163 startingPage "164" @default.
- W2167917163 abstract "Standardized processes should be used in the identification and development of intermediate endpoint biomarkers (IEB) for the prediction of patient-specific disease outcomes. Using our own experiences, we outline some of our standardized processes. Using computer-assisted image analysis, we developed a new biomarker of genetic instability, termed quantitative nuclear grade (QNG). The QNG biomarker is derived using nuclear images analyzed from the tumor areas of Feulgen-stained 5-microm biopsy or radical prostatectomy tissue sections. From the variances of 41 to 60 different nuclear size, shape, and chromatin organization features, a QNG solution is computed using either logistic regression or artificial neural networks. QNG can then be used as an input for models that solve for a patient-specific probability to accurately predict disease outcomes. Preoperatively, QNG predicted both the pathologic stage and progression of prostate cancer using biopsies (P <0.0001). Postoperatively, QNG proved extremely valuable in the prediction of biochemical progression using radical prostatectomy specimens with more than 10 years of follow-up (P <0.0001). We also demonstrate the identification of novel, differentially expressed, prostate cancer genes using RNA fingerprinting methods and the clinical utility of testing for these genes in both blood and tissue samples. Also illustrated is the improvement of serum biomarker performance by combining molecular forms of PSA with new biomarkers. In conclusion, the development of new IEBs requires planning based upon an understanding of the molecular pathogenesis of disease. IEB selection and clinical evaluation should employ standardized methods of testing and validation, followed by publication. QNG is 1 example of a new, highly predictive, IEB for prostate cancer that has been developed using these processes." @default.
- W2167917163 created "2016-06-24" @default.
- W2167917163 creator A5027278571 @default.
- W2167917163 creator A5035137850 @default.
- W2167917163 creator A5073431093 @default.
- W2167917163 date "2001-04-01" @default.
- W2167917163 modified "2023-10-14" @default.
- W2167917163 title "Standardization, analytical validation, and quality control of intermediate endpoint biomarkers" @default.
- W2167917163 cites W1547056266 @default.
- W2167917163 cites W1984464850 @default.
- W2167917163 cites W1998947396 @default.
- W2167917163 cites W2012364275 @default.
- W2167917163 cites W2045158748 @default.
- W2167917163 cites W2053773278 @default.
- W2167917163 cites W2057521311 @default.
- W2167917163 cites W2062213137 @default.
- W2167917163 cites W2091686071 @default.
- W2167917163 cites W2091772367 @default.
- W2167917163 cites W2113997135 @default.
- W2167917163 cites W2117680513 @default.
- W2167917163 cites W2120565180 @default.
- W2167917163 cites W2138178697 @default.
- W2167917163 cites W2152760636 @default.
- W2167917163 cites W4301868850 @default.
- W2167917163 doi "https://doi.org/10.1016/s0090-4295(00)00965-1" @default.
- W2167917163 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11295618" @default.
- W2167917163 hasPublicationYear "2001" @default.
- W2167917163 type Work @default.
- W2167917163 sameAs 2167917163 @default.
- W2167917163 citedByCount "14" @default.
- W2167917163 crossrefType "journal-article" @default.
- W2167917163 hasAuthorship W2167917163A5027278571 @default.
- W2167917163 hasAuthorship W2167917163A5035137850 @default.
- W2167917163 hasAuthorship W2167917163A5073431093 @default.
- W2167917163 hasConcept C121608353 @default.
- W2167917163 hasConcept C126322002 @default.
- W2167917163 hasConcept C142724271 @default.
- W2167917163 hasConcept C143998085 @default.
- W2167917163 hasConcept C2775934546 @default.
- W2167917163 hasConcept C2776235491 @default.
- W2167917163 hasConcept C2779466945 @default.
- W2167917163 hasConcept C2780192828 @default.
- W2167917163 hasConcept C2781197716 @default.
- W2167917163 hasConcept C55493867 @default.
- W2167917163 hasConcept C71924100 @default.
- W2167917163 hasConcept C86803240 @default.
- W2167917163 hasConceptScore W2167917163C121608353 @default.
- W2167917163 hasConceptScore W2167917163C126322002 @default.
- W2167917163 hasConceptScore W2167917163C142724271 @default.
- W2167917163 hasConceptScore W2167917163C143998085 @default.
- W2167917163 hasConceptScore W2167917163C2775934546 @default.
- W2167917163 hasConceptScore W2167917163C2776235491 @default.
- W2167917163 hasConceptScore W2167917163C2779466945 @default.
- W2167917163 hasConceptScore W2167917163C2780192828 @default.
- W2167917163 hasConceptScore W2167917163C2781197716 @default.
- W2167917163 hasConceptScore W2167917163C55493867 @default.
- W2167917163 hasConceptScore W2167917163C71924100 @default.
- W2167917163 hasConceptScore W2167917163C86803240 @default.
- W2167917163 hasIssue "4" @default.
- W2167917163 hasLocation W21679171631 @default.
- W2167917163 hasLocation W21679171632 @default.
- W2167917163 hasOpenAccess W2167917163 @default.
- W2167917163 hasPrimaryLocation W21679171631 @default.
- W2167917163 hasRelatedWork W2023983407 @default.
- W2167917163 hasRelatedWork W2066092646 @default.
- W2167917163 hasRelatedWork W2075009997 @default.
- W2167917163 hasRelatedWork W2075763133 @default.
- W2167917163 hasRelatedWork W2084343070 @default.
- W2167917163 hasRelatedWork W2088520467 @default.
- W2167917163 hasRelatedWork W2141682962 @default.
- W2167917163 hasRelatedWork W2376423713 @default.
- W2167917163 hasRelatedWork W1583600832 @default.
- W2167917163 hasRelatedWork W2023475404 @default.
- W2167917163 hasVolume "57" @default.
- W2167917163 isParatext "false" @default.
- W2167917163 isRetracted "false" @default.
- W2167917163 magId "2167917163" @default.
- W2167917163 workType "article" @default.